Characteristics | Year 1, n = 198 | Year 3, n = 149 |
---|---|---|
MTX dose, mg/week, median (IQR) | 20.0 (10.0–25.0) | 15.0 (8.75–25.0) |
MTX dose ≥ 20 mg/week, n (%) | 108 (54.5) | 61 (40.9) |
SSZ dose, g/day, median (IQR) | 2.0 (0.0–3.0) | 2.0 (0.0–3.0) |
SSZ dose ≥ 2 g/day, n (%) | 114 (57.8) | 79 (53.0) |
HCQ dose, mg/day, median (IQR) | 400.0 (0) | 400.0 (0) |
Concomitant DMARD, n (%) | ||
Leflunomide | 65 (32.8) | 75 (50.3) |
Gold injection | 8 (4.0) | 23 (15.4) |
Biologics | 3 (1.5) | 14 (9.4) |
Cyclosporine | 1 (0.5) | 4 (2.7) |
Azathioprine | 1 (0.5) | 2 (1.3) |
Injectable corticosteroids, n (%) | 120 (60.6) | 108 (72.3) |
MTX: methotrexate; SSZ: sulfasalazine; HCQ: hydroxychloroquine; DMARD: disease-modifying antirheumatic drug.